Contribution: Industrial Research Assistance Program – Contributions to Firms
ImmunoVaccine Technologies Inc.
$2,655,429.00
COVID-19 Response (VI): DPX-COVID-19 Clinical Development and DPX-CoVLP Proof-of-Concept Study
FY 2020-21 · 2020-09-04
Summary
In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-19 pandemic. We believe our targeted peptide epitope approach has the potential to optimize and exceed the safety and efficacy profile of more conventional vaccines. DPX-COVID-19 utilizes a multi-target approach, to optimize immune response against virus’ weaknesses, enhance efficacy at preventing infection and reduce potential for immune escape, even in case of a virus mutation. Fully synthetic, DPX-COVID-19 has the potential for fast and large-scale manufacturing to supply a significant number of doses rapidly compared to more conventional vaccines.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Dartmouth|Dartmouth, Nova Scotia, Canada
Recipient Type
For-profit organization
Business Number
864736772
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 1 | 2020-09-04 | 2020-21 | $5,412,045.00 |
| 2 | 2020-09-04 | 2020-21 | $5,887,037.00 |
| 3 | 2020-09-04 | 2020-21 | $5,887,037.00 |
| 4 | 2020-09-04 | 2020-21 | $3,791,179.00 |
| 5 | 2020-09-04 | 2020-21 | $2,655,429.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is -1,135,750 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de -1 135 750 dollars.
Agreement End Date
2022-08-31
Agreement Number
957553
Agreement Start Date
2020-09-04
Agreement Title
COVID-19 Response (VI): DPX-COVID-19 Clinical Development and DPX-CoVLP Proof-of-Concept Study
Agreement Title (French)
Réponse à la COVID-19 (VI) : Développement clinique du DPX-COVID-19 et étude de preuve de concept du DPX-CoVLP
Agreement Type
Contribution
Agreement Value
$2,655,429.00
Amendment Date
2023-02-27
Amendment Number
5
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-19 pandemic. We believe our targeted peptide epitope approach has the potential to optimize and exceed the safety and efficacy profile of more conventional vaccines. DPX-COVID-19 utilizes a multi-target approach, to optimize immune response against virus’ weaknesses, enhance efficacy at preventing infection and reduce potential for immune escape, even in case of a virus mutation. Fully synthetic, DPX-COVID-19 has the potential for fast and large-scale manufacturing to supply a significant number of doses rapidly compared to more conventional vaccines.
Description (French)
En réponse à la crise mondiale, IMV a lancé le développement d'un vaccin destiné à protéger contre la pandémie de COVID-19. Nous pensons que notre approche ciblée par épitope peptidique a le potentiel d'optimiser et de dépasser le profil de sécurité et d'efficacité des vaccins plus conventionnels. Le DPX-COVID-19 repose sur une approche multi-cibles, afin d'optimiser la réponse immunitaire contre les faiblesses du virus, d'améliorer l'efficacité de la prévention de l'infection et de réduire le potentiel d'échappement immunitaire, même en cas de mutation du virus. Entièrement synthétique, le DPX-COVID-19 peut être fabriqué rapidement et à grande échelle afin de fournir rapidement un nombre important de doses par rapport aux vaccins plus conventionnels.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Dartmouth--Cole Harbour
Federal Riding (French)
Dartmouth--Cole Harbour
Federal Riding Number
12004
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
864736772
Recipient City
Dartmouth|Dartmouth
Recipient Country
CA
Recipient Legal Name
ImmunoVaccine Technologies Inc.
Recipient Postal Code
B3B 2C4
Recipient Province or Territory
NS
Recipient Type
F
Reference Number
172-2020-2021-Q3-957553
